International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age

European Journal of Cancer

Volumn 42, Issue 8, 2006, Pages 1113-1119

  Sano, Hideki ^a   Bonadio, Jeffrey ^a   Gerbing, Robert B ^b   London, Wendy B ^c   Matthay, Katherine K ^d   Lukens, John N ^e   Shimada, Hiroyuki ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c University of Florida   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

Age; International neuroblastoma pathology classification; Neuroblastoma; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CELL DIFFERENTIATION; CHILD; CONTROLLED STUDY; EVALUATION; HISTOPATHOLOGY; HUMAN; INFANT; MITOSIS; NEUROBLAST; NEUROBLASTOMA; NEWBORN; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HUMANS; INFANT; INFANT, NEWBORN; NEUROBLASTOMA; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PROGNOSIS;

EID: 33646505929     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.031     Document Type: Article

References (32)

1. Stiller C.A. Epidemiology and genetics of childhood cancer. Oncogene 23 (2004) 6429-6444
2. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev Cancer 3 (2003) 203-216
3. Weinstein J.L., Katzenstein H.M., and Cohn S.L. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8 (2003) 278-292
4. Evans A.E., D'Angio G.J., Propert K., Anderson J., and Hann H.W. Prognostic factors in neuroblastoma. Cancer 59 (1987) 1853-1859
5. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 (1993) 1466-1477
6. Evans A.E., D'Angio G.J., and Randolph J. A proposed staging for children with neuroblastoma. Cancer 27 (1971) 374-378
7. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplifications of N- myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
8. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N- myc oncogene with rapid progression of the neuroblastomas. N Engl J Med 313 (1985) 1111-1116
9. Look A.T., Hayes F.A., Shuster J.J., et al. Clinical relevance of tumor cell ploidy and N- myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9 (1991) 581-591
10. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., and Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86 (1999) 349-363
11. Shimada H., Ambros I.M., Dehner L.P., et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 86 (1999) 364-372
12. Sutow W.W. Prognosis of neuroblastoma in childhood. Am J Dis Child 96 (1958) 299-305
13. Gross R.E., Farber S., and Martin L.W. Neuroblastoma sympatheticum, a study and report of 217 cases. Pediatrics 23 (1959) 1179-1191
14. Matthay K.K. Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin 45 (1995) 179-192
15. Castleberry R.P., Shuster J.J., and Smith E.I. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 12 (1994) 2378-2381
16. Schmidt M.L., Lal A., Seeger R.C., et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group study. J Clin Oncol 23 (2005) 6474-6780
17. George R.E., London W.B., Cohn S.L., et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 23 (2005) 6466-6473
18. London W.B., Castleberry R.P., Matthay K.K., et al. Evidence for an age cut-off greater 365 days for than neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23 (2005) 6459-6465
19. Shimada H., Chatten J., Newton W.A., et al. Histopathologic prognostic factors in neuroblastic tumours: definition of subtypes of ganglioneuroblastoma and age-linked classification of neuroblastomas. J Natl Cancer Inst 73 (1984) 405-416
20. Peuchmaur M., d'Amore E.S.G., Joshi V.V., et al. Revision of International Neuroblastoma Pathology Classification: Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 (2003) 2274-2281
21. Perez C.A., Matthay K.K., Atkinson J.B., et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol 18 (2000) 18-26
22. Matthay K.K., Perez C.A., Seeger R.C., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 16 (1998) 1256-1264
23. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341 (1999) 1165-1173
24. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
25. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35 (1977) 1-39
26. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J Royal Stat Soc [Series A] 135 (1972) 185-198
27. Cox D.R. Regression Models and Life Tables (with discussion). J Royal Stat Soc [Series B] 34 (1972) 187-220
28. Maris J.M., and Matthay K.K. Molecular biology of neuroblastoma. J Clin Oncol 17 (1999) 2264-2279
29. Shimada H., Stram D.O., Chatten J., et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87 (1995) 1470-1476
30. Goto S., Umehara S., Gerbing R.B., et al. Histopathology and MYCN status in peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92 (2001) 2699-2708
31. Kobayashi C., Monforte-Munoz H.L., and Gerbing R.B. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 103 (2005) 174-180
32. Shimada H., Nakagawa A., Peters J., et al. TrkA expression in peripheral neuroblastic tumors. Cancer 101 (2004) 1873-1881